Compile Data Set for Download or QSAR
Report error Found 435 Enz. Inhib. hit(s) with all data for entry = 8982
TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434080(US10562891, Example 2 | US11008308, Example 2)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434086(US10562891, Example 8 | US11008308, Example 8)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434091(US10562891, Example 13 | US11008308, Example 13)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434096(US10562891, Example 18 | US11008308, Example 18)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434098(US10562891, Example 20 | US11008308, Example 20)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434099(US10562891, Example 21 | US11008308, Example 21)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434100(US10562891, Example 22 | US11008308, Example 22)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434101(US10562891, Example 23 | US11008308, Example 23)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent
PDB3D3D Structure (crystal)
TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434111(US10562891, Example 33 | US11008308, Example 33)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434112(US10562891, Example 34 | US11008308, Example 34)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434113(US10562891, Example 35 | US11008308, Example 35)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434122(US10562891, Example 44 | US11008308, Example 44)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434129(US10562891, Example 51 | US11008308, Example 51)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434131(US10562891, Example 53 | US11008308, Example 53)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434134(US10562891, Example 56 | US11008308, Example 56)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434135(US10562891, Example 57 | US11008308, Example 58)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434136(US10562891, Example 58)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434137(US10562891, Example 59 | US11008308, Example 59)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434138(US10562891, Example 60 | US11008308, Example 61)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434139(US10562891, Example 61)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434140(US10562891, Example 62 | US11008308, Example 63)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434142(US10562891, Example 64 | US11008308, Example 65)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434144(US10562891, Example 66 | US11008308, Example 66)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434145(US10562891, Example 67 | US11008308, Example 68)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434147(US10562891, Example 69 | US11008308, Example 69)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434151(US10562891, Example 73 | US11008308, Example 73)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434157(US10562891, Example 79 | US11008308, Example 79)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434158(US10562891, Example 80 | US11008308, Example 80)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434172(US10562891, Example 94 | US11008308, Example 94)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434176(US10562891, Example 98 | US11008308, Example 98)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434178(US10562891, Example 100 | US11008308, Example 100)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434179(US10562891, Example 101 | US11008308, Example 101)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434180(US10562891, Example 102 | US11008308, Example 102)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434181(US10562891, Example 103 | US11008308, Example 103)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434183(US10562891, Example 105 | US11008308, Example 105)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434185(US10562891, Example 107 | US11008308, Example 107)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434186(US10562891, Example 108 | US11008308, Example 108)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434193(US10562891, Example 115 | US11008308, Example 115)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434194(US10562891, Example 116 | US11008308, Example 116)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434197(US10562891, Example 119 | US11008308, Example 119)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434199(US10562891, Example 121 | US11008308, Example 121)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434200(US10562891, Example 122 | US11008308, Example 122)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434201(US10562891, Example 123 | US11008308, Example 123)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434202(US10562891, Example 124 | US11008308, Example 124)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434214(US10562891, Example 136 | US11008308, Example 136)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434215(US10562891, Example 137 | US11008308, Example 137)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434216(US10562891, Example 138 | US11008308, Example 138)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434217(US10562891, Example 139 | US11008308, Example 139)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434218(US10562891, Example 140 | US11008308, Example 140)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

TargetProtein mono-ADP-ribosyltransferase PARP14 [1611-1801](Human)
Ribon Therapeutics

US Patent
LigandPNGBDBM434220(US10562891, Example 142 | US11008308, Example 142)
Affinity DataIC50: 1.00E+3nMAssay Description:Enzymatic inhibition of PARP14 was measured using a dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA) monitoring the auto-modificati...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/22/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 435 total ) | Next | Last >>
Jump to: